In search of elu­sive NASH break­through, Pfiz­er spot­lights com­bo ap­proach

Pfiz­er’s sec­ond crack at steer­ing a NASH can­di­date through a bat­tered field seems to be go­ing bet­ter than the first.

The phar­ma gi­ant has scored the FDA’s fast track des­ig­na­tion for an ex­per­i­men­tal com­bi­na­tion ther­a­py as a treat­ment for NASH with liv­er fi­bro­sis. The com­bo con­sists of er­vo­ga­s­tat, a di­a­cyl­glyc­erol O-acyl­trans­ferase 2 in­hibitor (DGAT2i), and cle­saco­stat, an acetyl-CoA car­boxy­lase in­hibitor (AC­Ci).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER